Millipore Sigma Vibrant Logo
Atención: Nos hemos mudado. Los productos Merck Millipore ya no pueden adquirirse en MerckMillipore.comMás información

AG938-1MG Synuclein, α, recombinant human

Synuclein, α, recombinant human: Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.
UniProt Number: P37840 Entrez Gene Number: NM_000345.2, NM_007308.1
AG938-1MG
1 mg  
Purchase on Sigma-Aldrich

Descripción

Replacement Information
Description
Catalogue NumberAG938-1MG
Brand Family Chemicon®
Trade Name
  • Chemicon
DescriptionSynuclein, α, recombinant human
OverviewAlpha Synuclein.

MOL. WT.: 14,459.7 Da by Mass Spec Analysis (theoretical 14,460)

PEPTIDE CONTENT: 1 mg per vial (protein content and concentration determined by BCA protein assays using BSA as standard).
References
Product Information
PresentationLyophilized from TBS. Resuspend in water at a concentration of 1 mg/mL
Quality LevelMQ100
Applications
Biological Information
Purity>95% (determined by gel scan and mass spec)
Entrez Gene Number
Entrez Gene SummaryAlpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Two alternatively spliced transcripts of SNCA have been identified. Additional splicing may be present but the full-length nature of these variants has not been determined.
Gene Symbol
  • SNCA
  • alpha-synuclein
  • NACP
  • MGC110988
  • PARK1
  • PARK4
  • Alpha-synuclein
  • PD1
UniProt Number
UniProt SummaryFUNCTION: SwissProt: P37840 # May be involved in the regulation of dopamine release and transport. Soluble protein, normally localized primarily at the presynaptic region of axons, which can form filamentous aggregates that are the major non amyloid component of intracellular inclusions in several neurodegenerative diseases (synucleinopathies). Induces fibrillization of microtubule- associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase 3 activation.
SIZE: 140 amino acids; 14460 Da
SUBUNIT: Soluble monomer which can form filamentous aggregates. Interacts with UCHL1 (By similarity). Interacts with phospholipase D and histones.
SUBCELLULAR LOCATION: Cytoplasm. Membrane. Nucleus. Note=Membrane- bound in dopaminergic neurons. Also found in the nucleus.
TISSUE SPECIFICITY: Expressed principally in brain but is also expressed in low concentrations in all tissues examined except in liver. Concentrated in presynaptic nerve terminals.
DOMAIN: SwissProt: P37840 The NAC domain is involved in the fibril formation. The middle region forms the core of the filaments. The C-terminus may regulate aggregation and determine the diameter of the filaments.
PTM: Phosphorylated, predominantly on serine residues. Phosphorylation by CK1 appears to occur on residues distinct from the residue phosphorylated by other kinases. Phosphorylation of Ser-129 is selective and extensive in synucleinopathy lesions. In vitro, phosphorylation at Ser-129 promoted insoluble fibril formation. Phosphorylated on Tyr-125 by a PTK2B-dependent pathway upon osmotic stress. & Hallmark lesions of neurodegenerative synucleinopathies contain alpha-synuclein that is modified by nitration of tyrosine residues and possibly by dityrosine cross-linking to generated stable oligomers. & Ubiquitinated. The predominant conjugate is the diubiquitinated form (By similarity).
DISEASE: SwissProt: P37840 # Defects in SNCA are a cause of autosomal dominant Parkinson disease 1 (PARK1) [MIM:168601, 168600]. Parkinson disease (PD) is a complex, multifactorial disorder that typically manifests after the age of 50 years, although early-onset cases (before 50 years) are known. PD generally arises as a sporadic condition but is occasionally inherited as a simple mendelian trait. Although sporadic and familial PD are very similar, inherited forms of the disease usually begin at earlier ages and are associated with atypical clinical features. PD is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. & Defects in SNCA are the cause of Parkinson disease 4 (PARK4) [MIM:605543, 168600]. & Defects in SNCA are the cause of Lewy body dementia (DLB) [MIM:127750]. DLB is a neurodegenerative disorder clinically characterized by dementia and parkinsonism, often with fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Presence of Lewy bodies are the only essential pathologic features. & Deposition of fibrillar amyloid proteins intraneuronally as neurofibrillary tangles is characteristic of Alzheimer disease (AD). SNCA is a minor protein found within these deposits, but a major non amyloid component. & Brain iron accumulation type 1 (NBIA1, also called Hallervorden-Spatz syndrome), a rare neuroaxonal dystrophy, is histologically characterized by axonal spheroids, iron deposition, Lewy body (LB)-like intraneuronal inclusions, glial inclusions and neurofibrillary tangles. SNCA is found in LB-like inclusions, glial inclusions and spheroids.
SIMILARITY: Belongs to the synuclein family.
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsMaintain lyophilized material at -20ºC for up to 12 months after date of receipt. After reconstitution maintain at -20ºC to -70ºC for up to 2 weeks in undiluted aliquots. Avoid freeze/thaw cycles to avoid aggregation.
Packaging Information
Material Size1 mg
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Número de referencia GTIN
AG938-1MG 04053252584930

Documentation

Synuclein, α, recombinant human Ficha datos de seguridad (MSDS)

Título

Ficha técnica de seguridad del material (MSDS) 

Synuclein, α, recombinant human Certificados de análisis

CargoNúmero de lote
HUMAN ALPHA SYNUCLEIN (Recombinant, E. coli) - 2109491 2109491
HUMAN ALPHA SYNUCLEIN (Recombinant, E. coli) 3140973
HUMAN ALPHA SYNUCLEIN (Recombinant, E. coli) 3035246
HUMAN ALPHA SYNUCLEIN (Recombinant, E. coli) 3023488
HUMAN ALPHA SYNUCLEIN (Recombinant, E. coli) - 2029616 2029616
HUMAN ALPHA SYNUCLEIN (Recombinant, E. coli) - 3206386 3206386
HUMAN ALPHA SYNUCLEIN (Recombinant, E. coli) - 3227300 3227300
HUMAN ALPHA SYNUCLEIN (Recombinant, E. coli) - 3299970 3299970
HUMAN ALPHA SYNUCLEIN (Recombinant, E. coli) - 3379969 3379969
HUMAN ALPHA SYNUCLEIN (Recombinant, E. coli) - 3410100 3410100
Show more